[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Society of Interventional Oncology\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":63},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100582168","a-multi-center-observational-trial-of-symptomatic-high-risk-bone-metastases-treated-with-percutaneous-ablation-and-palliative-radiation-therapy-100582168",false,"NCT06859801","A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases Treated With Percutaneous Ablation and Palliative Radiation Therapy","TRIBUTE","Inclusion Criteria:\n\n* 1\\. Skeletal metastasis with localized pain not controlled medically \\[recall within last 24 hours of worst pain ≥ 5 using the BPI\\]\n* 2\\. Pain must be from one painful metastatic lesion involving the bone (additional less painful metastatic sites may be present). Extra-osseous extension of disease is allowed (must have some contact with the bone and be causing bone\u002Ftumor interface pain)\n* 3\\. Lesions that are at high-risk of skeletal related events defined as follows:\n* a. Minimum Spinal Instability Neoplastic Score (SINS) score ≥ 7 for lesions involving the spine\n* b. Pelvic and appendicular lytic lesions with or without cortical breakthrough causing functional\u002Fmechanical pain\n* 4\\. Target lesion amenable to percutaneous ablation with image guidance AND RT by specialists' review\n* 5\\. No prior targeted radiation therapy or ablation to the index lesion\n* 6\\. ECOG performance status 0-2\n* 7\\. Age ≥ 21 years\n* 8\\. Have signed the current approved informed consent form\n* 9\\. Willing and able to answer follow-up Patient Reported Outcomes (PRO) surveys (e.g., PROMIS®, BPI, COST-FACIT, and OMED) for up to 12 months\n* 10\\. Life expectancy \\> 3 months\n\nExclusion Criteria:\n\n* 1\\. Any medical or personal condition that, in the opinion of the site investigator, may potentially compromise the safety or compliance of the patient, or may preclude the patient's successful completion of the clinical trial.\n* 2\\. Target tumor involves a weight-bearing long bone of the lower extremity with the tumor causing \\> 50% loss of cortical bone \\[MIREL Score ≥ 7\\]\n* 3\\. Skeletal lesions with unstable pathologic fractures requiring immediate surgical stabilization\n* 4\\. Concurrent participation in other studies that could affect the primary endpoint\n* 5\\. Target tumor causing clinical or imaging evidence of spinal cord compression","ALL","21 Years",{"count":19,"type":20},120,"ESTIMATED","OBSERVATIONAL","The objective of this study is to evaluate real-world outcomes (e.g., pain, patient reported outcomes, skeletal related events, healthcare utilization, etc.) in patients treated with both percutaneous ablation and palliative radiation therapy (RT).",[24],"Bone Cancer Metastatic","RECRUITING","2026-06-04",{"date":28,"type":29},"2026-06-05","ACTUAL",{"date":31,"type":29},"2025-10-23",{"date":33,"type":20},"2027-07-31",{"name":35,"class":36},"Society of Interventional Oncology","OTHER",7,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":37},"100459634","ablation-with-confirmation-of-colorectal-liver-metastases-acclaim-100459634","NCT05265169","Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM)","Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM) Prospective Trial for Microwave Ablation as a Local Cure","ACCLAIM","Inclusion Criteria:\n\n1. Patient must be at least 18 years old.\n2. Patient has signed a written informed consent for the MWA and participation in the study.\n3. Patient with pathologically confirmed CRC with hepatic metastases confirmed on imaging (e.g., CT or MRI).\n4. Patient has up to 3 hepatic metastases, each up to 2.5 cm in largest diameter.\n5. Patient may have up to 5 lesions in the lung (none larger than ≥ 2.0 cm) and\u002For any lymph node ≤2.0 cm in the largest diameter\n6. Ability to safely create an ablation zone (AZ) that completely covers the tumor with minimal margin of 5.0 mm. Subcapsular (any tumor within 10 mm from the liver capsule) or perivascular (any tumor within 10 mm from a vessel larger than 3 mm) lesions may be included. For these tumors, the calculation of the margin will not apply to the area abutting the capsule or the vessel.\n7. The target tumor(s) is\u002Fare visible by US and\u002For CT in a location where MWA is technically achievable and safe based on the proximity to adjacent structures. Protective maneuvers such as hydrodissection for organ mobilization are allowed and will be recorded.\n8. ECOG performance status of 0-1.\n9. Platelet count \\>50,000\u002Fmm3 (correctable allowed) within 30 days prior to study treatment.\n\nExclusion Criteria:\n\n1. Patient is unable to lie flat or has respiratory distress at rest.\n2. Patient has uncontrolled and uncorrectable coagulopathy or bleeding disorders.\n3. Patient has a history of an allergic reaction to intravenous iodine that cannot be pre-medicated or prevents performance of a CT with IV contrast.\n4. Patient has evidence of active systemic infection.\n5. Patient has a debilitating medical or psychiatric illness that would preclude giving informed consent or receiving optimal treatment or follow up.\n6. Patient is currently participating in other experimental studies that could affect the primary endpoint.\n7. Patient unable to receive general anesthesia or adequate analgesia and sedation.\n8. Tumor location less than 25 mm from hilum (see diagrams with illustration of central ducts).\n9. Patient is currently pregnant or intends to become pregnant","18 Years",{"count":48,"type":20},275,"INTERVENTIONAL",[51],"NA","To demonstrate that microwave ablation (MWA) of up to 3 hepatic metastases, each with a maximum diameter of ≤ 2.5 cm will result in a 2-year local progression free survival of at least 90%. This is a standard of care (SOC) study.",[54],"Colorectal Liver Metastases","2024-01-16",{"date":57,"type":29},"2024-01-17",{"date":59,"type":29},"2023-01-13",{"date":61,"type":20},"2027-12-10",{"name":35,"class":36},""]